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Regional Centers of Excellence (RCEs) for
Biodefense and Emerging Infectious Diseases
Research
The National Institute of Allergy and Infectious
Diseases (NIAID) invites applications for funds to
develop Regional Centers of Excellence (RCEs) in
areas related to biodefense and emerging infectious
diseases research. The overall goal of the RCE pro-
gram is to develop and maintain strong infrastruc-
ture and multifaceted research and development
activities that will provide the scientific informa-
tion and translational research capacity to make
the next generation of therapeutics, vaccines, and
diagnostics against the CDC Category A–C Agents
(http://www.bt.cdc.gov/agent/agentlist.asp#
catagoryadiseases), with particular emphasis on
Category A.
To accomplish this goal, the RCEs will be pro-
vided with support to 1) develop and conduct pro-
grams of investigator-directed research; 2) train
researchers and other personnel for biodefense
research activities; 3) develop and maintain compre-
hensive core facilities to support the research and
training activities of the RCE; 4) develop transla-
tional research capacity for testing and validating
vaccine, therapeutic, and diagnostic concepts for
biodefense and emerging infectious diseases; 5)
maintain and make available core facilities and other
support to approved investigators from academia,
biotech companies, the pharmaceutical industry, and
other appropriate entities in the region for the pur-
pose of performing basic research and for testing and
evaluating vaccines, therapeutics, and diagnostics for
CDC Category A–C Agents; and 6) be ready and
available to provide facilities and scientific support
to first-line responders in the event of a national
biodefense emergency.
This RFA invites research institutions and
groups of investigators to form consortia and devel-
op applications for programs to address the funda-
mental research and development questions that
will provide the information needed to counter the
threat of bioterrorism. Diverse research and devel-
opment approaches are encouraged, as long as they
include the following essential features: a biode-
fense research focus on CDC Category A–C
Agents, particularly Category A, that incorporates a
translational component with the long-term goal of
developing testable products. 
A group of center member researchers with
expertise in biodefense and emerging infectious dis-
eases research is required to lead the research thrust
that underlies all the other activities of the RCE. In
addition, the RCE should designate specific plat-
forms and technologies that will serve as the basis
for the center’s development programs. Platforms
are cross-cutting technologies or experimental
approaches that integrate the research and develop-
ment activities. Examples of platforms include
genomics, proteomics, animal models, and preclini-
cal development, but others are welcome.
As identified by the recently convened NIAID
Blue Ribbon Panel on Bioterrorism and Its
Implications for Biomedical Research, there is a
critical need for the establishment of highly devel-
oped research and development infrastructure with
strong translational research capacity to implement
the Biodefense Research Agenda of the NIAID (for
more information, visit http://www.niaid.nih.gov/
dmid/bioterrorism/).
The following are examples of research within
the scope of the RCE program (for a more detailed
list of NIAID biodefense research priorities, appli-
cants are encouraged to consult the strategic plan):
1) basic biology of Category A–C Agents, with par-
ticular emphasis on Category A; 2) mechanisms of
pathogenesis of Category A–C Agents; 3) applica-
tion of genomic and proteomic strategies to
Category A–C Agents; 4) basic aspects of the
innate and adaptive immune responses to Category
A–C Agents; 5) rapid, sensitive, and specific
approaches for detection and identification of
Category A–C Agents; 6) target identification for
diagnostics, therapeutics, and vaccines, including
assay development; 7) development of new animal
models for pathogenesis studies, for therapeutics
and vaccine evaluation, and for rapid diagnostic
studies; and 8) testing through Phase I clinical tri-
als of drugs, diagnostics, and vaccines.
For fiscal year 2003 the NIAID intends to
commit approximately $40 million to fund up to 4
RCEs in response to this RFA. An applicant may
request a project period of up to five years. To
achieve nationwide distribution of the RCEs, the
NIAID has divided the United States into 10
regions. It is the long-range goal of this program,
contingent upon the availability of funds, to estab-
lish at least one RCE within each region.
Prospective applicants are asked to submit a
letter of intent by 15 November 2002, with final
applications due 15 January 2003. Applications
must be prepared using the PHS 398 research grant
application instructions and forms (rev. 5/2001),
available online at http://grants.nih.gov/
grants/funding/phs398/phs398.html in an interac-
tive format. In addition, applicants must consult
and use “Instructions for Applications for Multi-
Project Awards” (http://www.niaid.nih.gov/
ncn/grants/multibron.htm) with the additional
instructions specific to this RFA noted in the
online version available at http://grants1.nih.gov/
grants/guide/rfa-files/RFA-AI-02-031.html. 
Contact: Rona Hirschberg, Division of
Microbiology and Infectious Diseases, NIAID,
6700B Rockledge Drive, Room 3129, MSC 7630,
Bethesda, MD 20892-7630 USA, 301-496-1884,
fax: 301-480-4528, e-mail: rhirschberg@
niaid.nih.gov. Reference: RFA No. AI-02-031
Genetic Architecture, Biological Variation, and
Complex Phenotypes
This PA updates PA-98-078, “Genetic Architecture
of Complex Phenotypes.” The purpose of this PA
is to solicit applications for new studies on genetic
variation and the architecture of complex pheno-
types. It restates the interest of several components
of the NIH in studies of the underlying causes and
architecture of complex phenotypes, including
human diseases. It is motivated by the amount and
complexity of biological data that are being gener-
ated and by the understanding that complex phe-
notypes involve many genetic components that
evolve in a variety of environments. 
Complex phenotypes are those that exhibit
familial clustering, which may mean that there is
some genetic component, but that do not occur in
Mendelian proportions in pedigrees. Complex phe-
notypes may be continuous in distribution (e.g.,
height or blood pressure), or they may be dichoto-
mous (e.g., affected and not affected). The complex-
ity arises from the fact that one cannot accurately
predict the expression of the phenotype from knowl-
edge of the individual effects of individual factors
considered alone, no matter how well understood
each separate component may be. 
The past few decades of biological research
using largely a reductionist approach have yielded
vast amounts of data. In addition, genome
sequencing projects, as well as structural and func-
tional genomics initiatives, are producing data far
more rapidly than scientists can analyze them and
understand their implications to biology and to
health. As overwhelming as the current data are,
they are only the beginning. Protein structures,
DNA sequences, and gene expression patterns vary
among individuals, among species, among popula-
tions within a species, and across environments. It
will soon be possible to utilize information on
thousands of variable genetic sites to investigate
the relationships among genotypes, phenotypes,
and environments. 
The term genetic architecture refers to the full
range of genetic effects on a trait; however, when
studying variation on such a large scale, it is espe-
cially important to consider the context or envi-
ronments in which genetic variation arises, is
selected, and is maintained. Genetic architecture is
less a fixed property of the phenotype than a char-
acteristic of a phenotype in a particular popula-
tion. Genetic architecture is a moving target that
changes according to gene and genotype frequen-
cies, distributions of environmental factors, and
such biological properties as age and sex. 
Studies of variation or genetic architecture may
employ a variety of conceptual approaches. A
researcher may consider the combinatorial effects of
many variable sites, whether the scale is within a gene
or across a genome. Comparative genomics, where
the goal is to identify patterns of variation among
genomes, is also a productive way of identifying
attributes of variation, such as which genomic regions
are rapidly evolving. Another approach is to study
variation related to biological levels of organization,
such as DNA sequence, protein structure, metabolic
pathways, cell dynamics, individual phenotype, and
population characteristics. The following are typical
of research areas targeted by this initiative: 
Biological variation: Studies of genetic architec-
ture have historically focused on associations of
genotype and phenotype (e.g., between DNA mark-
ers and a disease). However, an organism is a unique
consequence of both genes and environment and is
created by complex interactions of multiple events
and forces. How genes are expressed depends on
their cellular, developmental, physiological, and
environmental context. This initiative encourages
research on biological variation and interactions such
as 1) variation in basic biological systems, including
sequences, structures, and pathways that direct
metabolism and development; 2) variation in these
systems within individuals, among individuals,
among populations, and among species with the goal
of learning how these complex systems interact and
evolve; 3) determination of the extent to which
genetic architecture is shared across populations and
among species; 4) effects of admixture, population
history, recombination, mutation, population struc-
ture, selection, and drift on the organization of vari-
ation; 5) collection and analysis of both new and
existing data; 6) tools and models for identifying and
measuring important contextual features; and 7)
measuring the impact of context on biological data. 
Evolution of genome properties: An emerging
area of research focuses on how properties of
genomes arise in evolutionary history. Such
research has important consequences for under-
standing genome organization and for interpreting
data on genetic and phenotypic variation. Such
research could include the evolution of haplotypes,
selection for genetic interactions, and the evolu-
tion of recombination and methylation patterns. 
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Extensions to other organisms: Many organisms
have been studied for their value in agriculture or
ecology. Thus, there is considerable information
about the population structure, natural history, and
genetics of these systems. It will be valuable to take
advantage of this wealth of information to study
variation in the natural settings in which it evolved.
Bioinformatics: The study of biological varia-
tion depends heavily on rich data sets; researchers
need the ability to access many kinds of informa-
tion (e.g., DNA sequence, protein structure,
development, natural history, and phenotype) in
organisms from different habitats, from different
populations, and from different species. This ini-
tiative supports development of tools to help
researchers use data from many databases to
address research questions. 
Improved dynamic modeling and statistical
methods: Mathematical approaches to studying bio-
logical variation have changed little in several
decades. There is a need to develop new dynamic
models to illuminate how systems interact and
evolve. Just as important, it is critical to study the
nature of biological and mathematical assumptions
of models and statistics. Tools for analyzing and
interpreting data on the architecture of complex
phenotypes should be developed in the context of
real biological information. Areas of particular
interest for this initiative include 1) implications
and appropriate uses of different sampling strate-
gies; 2) analytical tools to discover patterns of
genotypic variation and their roles in conferring
phenotype; 3) incorporation of data from new
technologies; 4) development of robust methods
that are compatible with real data (missing or
incomplete data, typing errors, experimental
errors); and 5) development of mathematical mod-
els based on empirical information, which includes
such biological realities as epistasis, recombination,
mutation, protein structure, cell biology, metabolic
pathways, development, population history, and
evolution.
Applications submitted in response to this PA
will be accepted at the standard application dead-
lines, available at http://grants.nih.gov/grants/
dates.htm. Complete information on this PA is
available at http://grants1.nih.gov/grants/guide/
pa-files/PA-02-110.html. Applications must be pre-
pared using the PHS 398 research grant application
instructions and forms (rev. 5/2001), available at
http://grants.nih.gov/grants/funding/phs398/phs398
.html in an interactive format. 
Contact: Irene Anne Eckstrand, Division of
Genetics and Developmental Biology, NIGMS, 45
Center Drive, MSC 6200, Bethesda, MD 20892-
6200 USA, 301-594-0943, fax: 301-480-2228, e-
mail: Irene_Eckstrand@nih.gov; Lisa Brooks,
NHGRI, 31 Center Drive, 31/B2B07, Bethesda,
MD 20892-2033 USA, 301-435-5544, fax: 301-
480-2770, e-mail: lisa_brooks@nih.gov; Winifred
Rossi, Genetic Epidemiology and Translational
Research, NIA, 7201 Wisconsin Avenue, Suite
3E327, Bethesda, MD 20892-9205 USA, 301-
496-3836, fax: 301-402-1784, e-mail: wr33a@
nih.gov; Lisa Neuhold, Division of Basic Research,
NIAAA, 6000 Executive Boulevard, Suite 402,
Bethesda, MD 20892-7003 USA, 301-594-6228,
fax: 301-594-0673, e-mail: lneuhold@
willco.niaaa.nih.gov; Steven Moldin, Genetics
Research Branch, Division of Neuroscience &
Basic Behavioral Science, NIMH, 6001 Executive
Boulevard, Room 7189, MSC 9643, Bethesda,
MD 20892-9643 USA, 301-443-2037, fax: 301-
443-9890, e-mail: smoldin@mail.nih.gov; Robert
Karp, Division of Digestive Diseases and
Nutrition, NIDDK, 6707 Democracy Boulevard,
Room 671, MSC 5450, Bethesda, MD 20892-
5450 USA, 301-451-8875, fax: 301-480-8300, e-
mail: karpr@extra.niddk.nih.gov; Jonathan
Pollock, Genetics and Molecular Neurobiology
Research Branch, NIDA, 6001 Executive
Boulevard, Room 4274, Bethesda, MD 20892
USA, 301-435-1309, fax: 301-594-6043, e-mail:
jp183r@nih.gov; Jose Velazquez, Division of
Extramural Research and Training, NIEHS, 111
Alexander Drive, Research Triangle Park, NC
27709 USA, 919-541-4998, fax: 919-316-4606, e-
mail: velazqu1@niehs.nih.gov; or Katrina Gwinn-
Hardy, NINDS, 6100 Executive Boulevard, Room
2142, MSC 9525, Bethesda, MD 20892 USA, 301-
496-5745, fax: 301-402-1501, e-mail: gwinnk@
ninds.nih.gov. Reference: PA No. PA-02-110
Integrated Biomedical Technology Research
Resources for Proteomics and Glycomics
The National Center for Research Resources
(NCRR) proposes to foster the development of
improved technologies and methods for pro-
teomics and glycomics research by sponsoring
integrated biomedical technology research
resources through the P41 mechanism. One way
to confront the growing analytical challenges of
the genome era is to pursue technology develop-
ment primarily along integrated lines of inquiry
rather than single technologies. This is particularly
true in the field of proteomics. The focus of these
integrated research resources will be to develop a
range of innovative analytical tools and methods,
and apply these tools to biologically significant
problems. The resources will also provide broad
access to these integrated technologies through
collaboration, service, training, and dissemination
activities.
Proposed integrated research resource centers
should focus on the core technological and
methodological problems of proteomics.
Responses with special expertise in analytical
glycobiology are encouraged, and this solicitation
is open to unconventional or alternative approach-
es. Regardless of the specific experimental
approaches taken in proteomics experiments, a
common theme in this field is the need for synergy
among three principal domains: 1) biological com-
petencies, 2) analytical chemistry, and 3) computa-
tional tools. These domains should each inform
the development of tools and methods in their
counterpart areas. Accomplishing this goal in a cli-
mate of specialization demands a fundamentally
collaborative approach.
It is anticipated that these integrated centers
may be significantly larger and more complex than
a more narrowly defined research resource. These
centers may be expected to draw together the
expertise of experienced investigators whose areas
of specialization and established research focus will
contribute to the overall goals of the project.
Because of the need for integration of technologies
at a fundamental level, it is considered critical that
participating investigators be in a position to work
closely together in an iterative manner. 
Development of complex integrated
approaches to proteomics problems will require a
context within which development of methods can
proceed. Investigators may wish to select a model
system or define a biological research topic that
will serve as a framework for the technological
research and development activities of the 
resource. Investigators will be expected to clearly
define the scope of their activities, and this defini-
tion should inform their choice of biological con-
text, if any.
Integrated research resources in proteomics
will eventually be expected to have a broad-based
significant impact on a variety of biological prob-
lems, through both collaborative projects and
those initiated within the resource. However, ulti-
mately the most important deliverables will be
state-of-the-art technology and methods for pro-
teomics research.
Posttranslational modification is a point of
concern in the development of strategies for pro-
teomics. Because these modifications cannot be
inferred directly from gene sequence, they general-
ly can only be characterized directly. This raises
issues about sequence coverage and stoichiometry
of modifications that are not presented by pro-
teomics problems focused on protein identifica-
tion. In particular, the complexity and diversity of
glycosylation events significantly complicates the
linkage between genetic sequence and mature,
active proteins. Because glycosylation is mediated
by a wide range of factors, discovery-based analyti-
cal tools that can survey the complexities of glyco-
sylation on a systemwide basis may have signifi-
cant biological impact.
Besides obstacles presented by proteomics in
general, glycobiology-focused proteomics (gly-
comics) requires the development of novel
approaches and tools directed at the special chal-
lenges of glycobiology. Strategies for separation,
profiling, quantitation, and detailed characteriza-
tion of carbohydrate structures are central chal-
lenges. Bioinformatics tools are needed for data
handling and reduction, correlation of carbohy-
drate and protein information, recognizing shifts
in glycoprotein microheterogeneity, and model
building. Synthesis, 3-D structural analysis, and a
variety of other carbohydrate-specific analytical
tools may prove necessary to varying degrees,
depending on the global strategies adopted and
thematic focus of a center.
Ultimately, laboratories engaged in glycomics
will need the tools of mainstream proteomics as
well as these additional specialized capabilities.
Because of the breadth of challenges inherent in
developing effective tools in both proteomics and
glycomics, we encourage laboratories with special
expertise in analytical glycobiology to address
those technological problems that are inherent in
and unique to glycomics.
The deadline for letters of intent is January 1,
May 1, and September 1. Applications must be
prepared using the PHS 398 research grant appli-
cation instructions and forms (rev. 5/2001). The
PHS 398 is available at http://grants.nih.gov/
grants/funding/phs398/phs398.html in an interac-
tive format. Complete information on this
announcement is available at http://grants1.nih.
gov/grants/guide/pa-files/PA-02-132.html.
Contact: Douglas M. Sheeley, Division of
Biomedical Technology, NCRR, 6705 Rockledge
Drive, MSC 7965, Bethesda, MD 20892-7965
USA, 301-435-0755, fax: 301-480-3659, e-mail:
sheeleyd@ncrr.nih.gov. Reference: PA No. PA-02-
132
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